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ABSTRACT
Cryptococcosis is a major invasive fungal disease related worldwide with the AIDS 
population. New reports of HIV/AIDS cases to the national public health surveillance system 
(SIVIGILA) in Colombia have shown that there is a growing community at risk of contracting 
cryptococcosis throughout the country who do not have access to ART. Even though the most 
prevalent species Cryptococcus neoformans is mainly associated with the HIV population, 
we report a fatal case of cryptococcosis in an AIDS patient in Barranquilla, associated with 
Cryptococcus gattii VGI, isolated from blood culture. 
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INTRODUCTION
Cryptococcosis is a life threatening mycosis that affects humans among other 
vertebrates. Approximately one million cases are annually reported globally, 
particularly among HIV/AIDS patients in sub-Saharan Africa where the greatest 
burden of this syndrome is identified (estimated mortality ranges between 50% and 
70%, ranking fourth above tuberculosis)1. Since a significant number of cases of 
this mycosis has been reported in the HIV population, it is considered an AIDS-
defining condition2. 
The main etiological agents of cryptococcosis are two basidiomycetous 
yeasts, Cryptococcus neoformans species complex and Cryptococcus gattii 
species complex. Cryptococcus neoformans can be further classified in two 
varieties, Cryptococcus neoformans var. grubii and Cryptococcus neoformans 
var. neoformans; both species complex can be differentiated into four serotypes 
(A and D, or B and C, respectively), several hybrids (AD, AB, and BD), and 
eight molecular types (molecular types VNI-VNIV, and VGI-VGIV)3,4. More 
recently, a new taxonomy for C. neoformans and C. gattii comprising seven species 
has been recently proposed5. 
Different environments in rural and urban settings are the natural habitat for 
these species and the infection starts after inhaling infectious propagules, desiccated 
blastoconidia or basidiospores (sexual stage). Studies have suggested that eight 
molecular types are distributed within South America and at least seven circulate 
in Colombia6,7. 
Cryptococcosis does not require compulsory notification to public health in 
Colombia but different reports confirm its importance8-10. A national survey designed 
according to the guidelines established by the European Confederation of Medical 
Mycology and approved by the Ethics Committee of the Instituto Nacional de 
Salud (INS) has been carried out voluntarily at medical institutions (public and 
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private) throughout the country since 1997 and health 
professionals complete the forms. Risk factor information 
or whenever cryptococcosis has been an AIDS defining 
illness are inquired in addition to the diagnosis date, clinical 
findings, type of treatment, outcome, type of diagnostic 
assays employed (clinical laboratory/image) and treatment. 
According to the Colombian Cryptococcosis Study 
Group, the mean annual incidence rates of cryptococcosis 
2006-2010 in the general population was 2.4 × 106 
individuals; in AIDS patients the rate was 3.3 × 103 
individuals. C. neoformans var. grubii was prevalent 
(96.7%) in comparison with C. gattii (2.2%)9,10.
This is the first report of cryptococcosis caused by 
Cryptococcus gattii, VGI, in an HIV/AIDS male patient 
in Barranquilla, Colombia, with pulmonary manifestations 
without antiretroviral treatment (ART). 
CASE REPORT 
A 53-year-old male resident in Barranquilla, Colombia, 
was referred to a tertiary care hospital facility by his 
government affiliated medical service in February of 2012 
and admitted to the emergency service with poor clinical 
conditions, a notorious decrease of muscular mass and 
generalized motor deficit, and reporting three days of 
intense coughing, copious expectoration, fever, pain in 
right hemithorax, and dyspnea. Additionally, he reported 
general weakness, weight loss (20 Kg) during the last three 
months and several hospital admissions due to dyspnea and 
pneumonia in the past year. As relevant background, the 
patient had been previously diagnosed with HIV/AIDS, 
confirmed through a Western-Blot analytical technique one 
month prior to this episode. At admission to hospital, he 
reported to be unemployed and he was not receiving ART. 
During the physical examination, the patient appeared 
very anxious, presented isochoric and photoreactive pupils 
showing no meningeal signs, left cervical lymphadenopathies 
and generalized skin blemishes. Preliminary diagnosis 
included HIV/AIDS, community-acquired pneumonia, 
pulmonary tuberculosis, protein energy-malnutrition and 
oral candidiasis.
During hospitalization, clinical tests performed on 
day 2 confirmed an anemic condition and the metabolic 
panel testing did not show significant results. The patient 
underwent several immunologic tests for Hepatitis B and 
C with negative results; tuberculosis was also ruled out; the 
cytomegalovirus anti-IgM results were positive, as well as 
the total CORE antibody. CD4 count and viral load results 
were not available. 
Regarding microbiological studies, two blood cultures 
were performed on day 1 and at day 3. Both blood cultures 
(Bactec 9000 PLUS Aerobic/f; Becton Dickinson) were 
performed in duplicate, following the recommendations for 
clinical microbiology reported by the Sociedad Española 
de Enfermedades Infecciosas y Microbiología Clínica 
(SEIMC)11. From the first blood culture, one of two samples 
tested positive; from the second blood culture, both samples 
tested positive; a direct exam with India ink showed the 
encapsulated blastoconidia cells with micromorphological 
features suggestive of Cryptococcus spp. Isolation was 
possible after culturing the supernatant in 15 ml Columbia 
Agar (Becton Dickinson) with 5% sheep blood incubated 
at 37 °C, from which pure creamy yeast like colonies were 
observed 48 hours later. The urease test was carried out 
individually in tubes with 2.5 ml Christensen Media from 
the yeast like colonies with positive results. The clinical 
laboratory reported Cryptococcus neoformans on day 9. 
Antifungal therapy with Amphotericin B (40 mg/day) 
plus Fluconazole (400 mg/day) was initiated after 
cryptococcosis was diagnosed; however, the patient’s 
hemodynamical condition deteriorated progressively and 
he died nine days after the onset of treatment and 20 days 
after hospital admission. 
The isolates were forwarded to the departmental public 
health laboratory in Barranquilla with the correspondent 
survey, and later to the Instituto Nacional de Salud (INS) 
in Bogotá, D.C. for confirmation (genus and species) and 
molecular typing. Phenotypic testing included conventional 
laboratory techniques, such as India ink method, melanin 
production in Guizotia abyssinica media, urease production 
and use of nitrates. Differentiation between Cryptococcus 
neoformans species complex and Cryptococcus gattii 
species complex was performed using Canavanine-
Glycine-Bromothymol Blue agar (CGB) and the isolate 
was identified as C. gattii. 
High-molecular-weight DNA was extracted from 
a pure culture according to modifications proposed by 
Ferrer et al.12. RFLP of the URA5 gene grouped the isolate 
into the molecular type VGI13. 
DISCUSSION
Cryptococcosis associated to C. neoformans species 
complex and C. gattii species complex is considered the 
second most common cause of life threatening mycoses 
globally, occurring in humans and animals. Since the 
emergence of AIDS, this fungal disease is more frequently 
diagnosed among HIV-positive individuals associated with 
the worldwide distributed species of C. neoformans in 80% 
of the cases and in less proportion with C. gattii in 20%3. 
From 1981 to 1990, the reports of cryptococcosis due to the 
AIDS epidemic reached a 1,500% increase2,14. 
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The spectrum of this pathology ranges from self-limiting 
manifestations to systemic disease, with a wide variety of 
clinical signs and symptoms. In this case, the patient’s signs 
and symptoms during his admission and physical evaluation 
were consistent with clinical presentation and characteristics 
described for this mycosis; lung disease was predominantly 
found (mainly cough, fever, malaise and dyspnea) over 
central nervous system infection, which is consistent with 
findings by different authors3,15. This is the first documented 
case in Barranquilla, Colombia, addressing the clinical 
and genotypic features of C. gattii molecular type VGI, as 
the etiological agent of cryptococcosis identified from the 
bloodstream of an HIV/AIDS male patient. 
Despite its lower prevalence, C. gattii is considered 
an emergent pathogen with a changing epidemiological 
behavior not fully understood yet, partly because of its 
low search in clinical laboratories and partly because 
it was unusually diagnosed in the American continent 
before 1999. Taxonomically, C. gattii was considered 
as a variety within the Cryptococcus species complex 
and more recently, it came to be accepted as the sibling 
of C. neoformans, a species that has been the subject of 
increased attention and epidemiological interest since 
the emergence of AIDS15. From the late 1990s, C. gattii 
won importance for causing the outbreaks in the pacific 
west coast of North America, starting in the province of 
British Columbia, Canada, and later expanding South to 
nearby regions of the United States. Furthermore, new 
cases have been also identified in the Eastern coast of 
North America15. In South America there have been more 
cases reported by this pathogen as well as isolates from 
natural sources7-10,14. A study regarding the prevalence 
of cryptococcosis in Atlántico, Colombia, showed that 
among the clinical isolates, C. gattii was responsible in 
2.4% of them, while C. neoformans was in 90.4%; in the 
environment, only C. neoformans var. grubii was isolated 
in nine of the 2,068 total samples collected16. 
C. gattii is found less frequently worldwide compared 
with its sibling, and the principal risk factors involved 
in this circumstance remain unclear, given the fact that 
this species mainly affects apparently healthy hosts. It is 
also known that the general distribution of VGI and VGII 
types from clinical and veterinary sources can overcome 
VGIII and VGIV, with VGII being more prevalent than 
VGI (47% over 34% among 980 global isolates)15. Even 
though there is evidence that associates cryptococcosis by 
C. gattii, molecular types VGI and VGII with cerebrospinal 
involvement in immunocompetent hosts, this clinical 
case shows that much more needs to be understood about 
the association between host immunological status and 
molecular types15. 
In terms of major virulence determinants, both species 
show similarities but considering the disease outcome in 
C. gattii infections, and taking into account that certain 
molecular types have proven to be more virulent than others, 
virulence seems to be the result of complex interactions, 
many of which are yet unknown15. 
Even though the incidence of cryptococcosis in 
developed countries is relatively steady since the advent 
of ART, its prevalence is increasing in the developing 
world. After sub-Saharan Africa and followed by Southern 
Asia, Latin America stands in the third place with 54,400 
yearly cryptococcal meningitis cases and 29,900 estimated 
deaths16. Isolation of clinical as well as environmental 
pathogenic species of Cryptococcus is not uncommon in 
Colombia8-10,16. In the national report (1997-2014), 1,535 
of the isolates from patients with cryptococcosis (79% with 
AIDS) correspond to C. neoformans and 52 to C. gattii17. 
Although more cases  of  cryptococcosis  in 
immunocompromised patients are associated with C. 
neoformans molecular type VNI, it is necessary to continue 
monitoring this mycosis in Colombia since the SIVIGILA 
data show there has been an upward trend in the annual 
reports of HIV/AIDS in Colombia since 2007. Cases 
reported in 2012 show that Barranquilla (capital city of 
the department of Atlántico) presented an incidence of 
33.7 x 105 inhabitants, more than twice compared with the 
national indicator (16.4 x 105 inhabitants); furthermore, the 
incidence reported in the department of Atlántico (19.4 x 105 
inhabitants) was also higher18. It is possible that many cases of 
cryptococcosis in Barranquilla and in Atlántico have not been 
reported suggesting a number of patients at risk. Additionally, 
it should not be ignored that the World Health Organization 
(WHO) declared in December 2010 that only 34% of the 
HIV patients in Colombia were receiving ART, indicating 
that untreated seropositive population is at higher risk of 
developing coinfections such as cryptococcosis19. These 
numbers are consistent with those found in a study held in 
Colombia in a tertiary care hospital, between 1996 and 2010 
where only 23.8% of the patients with AIDS were receiving 
ART8. Even though the patient in this case was diagnosed 
with AIDS prior to his hospital admission, he denied any 
treatment with ART, which could influence his outcome. 
Laboratory diagnosis of cryptococcosis is simple and 
usually involves microbiological/serological procedures, 
which have been in use for decades and are still currently 
valid. Commonly performed tests include direct visualization 
of the encapsulated blastoconidia from body fluids, such 
as CSF and sputum using India ink, but also from blood 
culture supernatant as detailed in this case. Subculturing in 
Sabouraud Dextrose agar media allows the isolation of the 
fungus after incubation at 37 °C/26 °C during 24-72 hours, 
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after which yeast like creamy colored colonies develop. 
Positive blood cultures have been reported in 47-71% 
of HIV-infected patients in comparison with 27% of 
uninfected patients2. Sequentially, in addition to common 
tests within species of this genus (India ink, urease and 
melanin production, and use of nitrates), CGB phenotypic 
test allows differentiation between both pathogenic species. 
Unfortunately, after the development of creamy yeast like 
colonies at 37 °C and morphologic identification of the 
encapsulated yeast cells through India ink direct exam, 
specific CGB test was not available in this hospital facility, 
only the urease test, which limited the accurate identification 
of C. gattii. Isolates were phenotypically and genotypically 
confirmed as C. gattii, genotype VGI when the isolates were 
forwarded to the national reference center. 
Moreover, beyond the evidence presented regarding this 
clinical case of cryptococcosis due to C. gattii molecular 
type VGI in an immunosuppressed patient, the first case 
reported in this part of the country that was included in 
the results of the study previously developed in Atlántico, 
Colombia, we emphasize the importance of timely diagnosis 
and follow-up of HIV patients without ART, taking into 
account the high risk of infection and further development 
of fatal diseases such as cryptococcosis. 
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